Health Articles
Power from the sun Free solar energy for generating power using photovoltaics As renewable energy systems have become more widespread, consumers and end users have become increasingly keen to generate their own electricity. Today, an efficient photovoltaic system offers the opportunity to make profitable use of free solar energy. By installing photovoltaic modules, users demonstrate their
AKTIENBRIEF Eine Publikation der DZ BANK und der WGZ BANK Ausgabe 30 / 1. August 2014 Überreicht durch Volksbank Schnathorst eGZuständige Aufsichtsbehörde: Bundesanstalt für Finanzdienstleistungsaufsicht ANLEGER SOLLTEN SICH VOR DER FED NICHT FÜRCHTEN Der S&P-500-Index konnte in der vergan- anderen Seite existiert eine Vielzahl von sich die Arbeitslosenquote zwar zuletzt
European Medicines Agency Veterinary Medicines and Inspections London, 13 October 2006 EMEA/CVMP/765/99-Rev.16 STATUS OF MRL PROCEDURES MRL assessments in the context of Council Regulation (EEC) No 2377/90 Background and legislative framework In order to protect the safety of the consumer of foodstuffs of animal origin, one of the most important principles laid down in the European Union (EU) legislation with regard to the marketing authorisation of veterinary medicines is that foodstuffs obtained from animals treated with veterinary medicinal products must not contain residues which might constitute a health hazard for the consumer. Before a veterinary medicinal product intended for food producing animals can be authorised in the EU, all pharmacologically active substances contained in the product have to undergo a safety and residues evaluation, and have to be included in Annex I, II, or III of Council Regulation (EEC) No 2377/901. The safety and residue evaluation in accordance with Regulation 2377/90 is carried out by the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMEA), supported by safety and residues experts, upon receipt of a valid application for the establishment of maximum residue limits (MRLs). Substances for which definitive MRLs have been established are included in Annex I of Regulation 2377/90. MRLs can be proposed as provisional, if all aspects are not yet fully addressed. In this case the substance is inserted in Annex III with an expiry date defining for the termination of the provisional status. However, no provisional MRLs can be proposed, if major issues with regard to safety remain to be addressed, as it must be assured that residues at the proposed levels do not present a hazard to the health of the consumer. Only, once the applicant has satisfactorily answered the outstanding questions, the substance can be included in Annex I. These questions are likely to relate to the provision of fully validated analytical methods. Where, following the evaluation, it appears that it is not necessary for the protection of public health to establish MRLs, such substance is included in Annex II. It should be noted that an entry in Annex II is not equivalent to the status "generally recognised as safe". In fact only a sub-group of Annex II substances do fall under this category. For further details on the assessment of a substance you are advised to consult the MRL Summary report of the substances concerned. Please also note that Annex II comprises a specific entry, which provides that certain substances approved in the EU as food additives with a valid E-number are considered included in Annex II without listing the substances specifically. Relevant substances falling under these provisions are e.g. vitamin C, citric acid or several sodium and potassium salts, and these substances are only mentioned in the enclosed list if an MRL application was submitted.
le magazine Bon été à tous ! La Treuillère 2015 n°43 CONTRÔLE TECHNIQUE VL - 4X4 - GAZ REMBERT DE LA HAYE EURL AUTO BILAN CONTRÔLE 148, RN 102 - 07200 LABEGUDE Tél. 04 75 88 94 31 Étienne & fils VIDANGE, CURAGE Ambulances V.S.L. - TAxiS ET DÉBOUCHAGE D'ÉGOUTS
The Open Natural Products Journal, 2010, 3, 10-19 An Initial Evaluation of the Safety, Efficacy and Purity of VigRX, a Herbal Combination Formula, for the Enhancement of Male Sexual Health Y. Smitasirib, P. D'Souzac, J. Neal-Kababick d and A.G. Schauss,*a aNatural and Medicinal Products Research, AIBMR Life Sciences, Inc., 4117 S. Meridian, Puyal up, Washington 98373, USA bMae Fah Luang University, Muang District, Chiang Rai 57100, Thailand cNatural Remedies, Plot 5B, 1t9
Tropical and Subtropical Agroecosystems, 1 (2003): 295 - 307 INDOLEALKYLAMINES IN MUCUNA SPECIES N. J. Szabo Tropical and Analytical Toxicology Core Laboratory, Center for Environmental and Human Toxicology, University of Florida, P.O.Box 110885, Gainesville, FL 32611-0885, USA E-mail: [email protected]
BOOK REVIEW Common and Uncommon Families and the American Constitutional Linda C. McClain* STATES OF UNION: FAMILY AND CHANGE IN THE AMERICAN CONSTITUTIONAL ORDER Mark E. Brandon. Lawrence: University of Kansas Press, 2014. INTRODUCTION: A FAMILIAR STORY ABOUT FAMILIES AND THE AMERICAN CONSTITUTIONAL ORDER . 19 BRANDON·S CONSTITUTIONAL STORY . 21
The Open Natural Products Journal, 2010, 3, 10-19 An Initial Evaluation of the Safety, Efficacy and Purity of VigRX, a Herbal Combination Formula, for the Enhancement of Male Sexual Health Y. Smitasirib, P. D'Souzac, J. Neal-Kababick d and A.G. Schauss,*a aNatural and Medicinal Products Research, AIBMR Life Sciences, Inc., 4117 S. Meridian, Puyal up, Washington 98373, USA bMae Fah Luang University, Muang District, Chiang Rai 57100, Thailand cNatural Remedies, Plot 5B, 1t9
Verein gegen Tierfabriken Schweiz VgT www.vgt.ch gegründet am 4. Juni 1989 Dr Erwin Kessler, Präsident Im Bühl 2, CH-9546 Tuttwil, Fax 052 378 23 62, Tel-Beantworter 052 378 23 01 Dr Daniel L. Vasella, NOVARTIS Dr Erwin Kessler, VgT Plädoyer und Verteidigungsschrift von Erwin Kessler teilweise mündlich vorgetragen und schriftlich eingereicht anlässlich der
Citation: Nutrition and Diabetes (2011) 1, e7; doi:10.1038/nutd.2011.3& 2011 Macmillan Publishers Limited All rights reserved 2044-4052/11 Metformin mitigates the impaired development ofskeletal muscle in the offspring of obese mice JF Tong1, X Yan1, JX Zhao1, MJ Zhu1, PW Nathanielsz2 and M Du1 1Developmental Biology Group, Department of Animal Science, University of Wyoming, Laramie, WY, USA and 2Center forPregnancy and Newborn Research, University of Texas Health Sciences Center, San Antonio, TX, USA
Psychotherapy Research 12(1) 1–21, 2002© 2002 Society for Psychotherapy Research HERMENEUTIC SINGLE-CASE EFFICACY DESIGN Robert ElliottUniversity of Toledo In this article, I outline hermeneutic single-case efficacy design (HSCED),an interpretive approach to evaluating treatment causality in single therapycases. This approach uses a mixture of quantitative and qualitative methodsto create a network of evidence that first identifies direct demonstrationsof causal links between therapy process and outcome and then evaluatesplausible nontherapy explanations for apparent change in therapy. I illus-trate the method with data from a depressed client who presented withunresolved loss and anger issues.
TÉRMINOS Y CONDICIONES DE COMPRA DE VALEO VALEO PURCHASING TERMS AND CONDITIONS Índice / Table of Contents Oferta; Aceptación, Términos Exclusivos / Offer; Acceptance; Exclusive Terms……………………………………. Cantidad y Vigencia / Quantity and Duration ………………………………………………………………………….
FICHA TÉCNICA O RESUMEN DE LAS CARACTERÍSTICAS DEL PRODUCTO NOMBRE DEL MEDICAMENTO Celecoxib VIR 200 mg cápsulas duras EFG COMPOSICIÓN CUALITATIVA Y CUANTITATIVA Cada cápsula contiene 200 mg de celecoxib. Excipiente(s) con efecto conocido: l a c t o s a Cada cápsula contiene 20,2 mg de lactosa monohidrato (ver sección 4.4)
